Clinical Trial

A new AI-designed eye drug gets clinical trial clearance, validating Matwings' iterative platform and signaling a major shift in biopharma R&D strategy.

A groundbreaking clinical trial is testing whether a common bone-strengthening drug can 'unmask' and eliminate the hidden HIV reservoir, a critical barrier to a cure.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

For glioblastoma patients, the wait for radiation is a race against time. A new device implanted during surgery is showing it can win that race.

New study shows a biosynthetic matrix matches allograft clinical outcomes while drastically cutting costs and prep time, signaling a major disruption for hospitals.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Bonerge is betting that cellular recovery is the key to mitigating the high cost of night shift work. Its real-world trial could redefine human capital investment.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

A new study shows 98% success for Mendaera's handheld robot. Beyond the launch, can this device truly bridge the gap in specialized medical skills?

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?